Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 14/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19608587 | 0.86 | HRH3 (0.61) | HPGDMAPTNPC1HRH3KMT2A | |
| SCHEMBL5796945 | 0.84 | HPGD (0.64) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL14140787 | 0.84 | HPGD (0.65) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL5796968 | 0.82 | NPC1 (0.70) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL7901274 | 0.81 | HPGD (0.71) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL21321950 | 0.81 | HPGD (0.71) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL27479149 | 0.80 | HPGD (1.00) | HPGDALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL7132525 | 0.80 | HPGD (1.00) | HPGDALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL5797269 | 0.80 | HPGD (0.74) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL300831 | 0.80 | HPGD (0.68) | HPGDALDH1A1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-0839134-B1 | BENZOYL PIPERIDINES/PYRROLIDINES FOR ENHANCING SYNAPTIC RESPONSE | UNIV CALIFORNIA (US) | 2004-02-18 | — | — | EP | disclosed |
| US-5783587-A | PSYCHOLOGICAL AND BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0839134-A1 | BENZOYL PIPERIDINES/PYRROLIDINES FOR ENHANCING SYNAPTIC RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5650409-A | FOR IMPROVING MEMORY, OR TREATING DEPRESSION, ALCOHOLISM OR SCHIZOPHRENIA | CORTEX PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996038414-A1 | BENZOYL PIPERIDINES/PYRROLIDINES FOR ENHANCING SYNAPTIC RESPONSE | CORTEX PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | HPGD 1202/4885ALDH1A1 4321/4885MAPT 461/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | HPGD 3434/4885ALDH1A1 2314/4885MAPT 352/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | HPGD 2739/4885ALDH1A1 2307/4885MAPT 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.